التفاصيل البيبلوغرافية
| العنوان: |
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. |
| المؤلفون: |
Shao, Shih-Chieh1,2 (AUTHOR), Chang, Kai-Cheng2,3 (AUTHOR), Lin, Swu-Jane4 (AUTHOR), Chang, Shang-Hung5,6 (AUTHOR), Hung, Ming-Jui7,8 (AUTHOR), Chan, Yuk-Ying9 (AUTHOR), Lai, Edward Chia-Cheng2 (AUTHOR) edward_lai@mail.ncku.edu.tw |
| المصدر: |
Cardiovascular Diabetology. 10/25/2021, Vol. 20 Issue 1, p1-11. 11p. |
| مصطلحات موضوعية: |
*EMPAGLIFLOZIN, *SODIUM-glucose cotransporter 2 inhibitors, *HEART failure, *CARDIOVASCULAR diseases, *PROPORTIONAL hazards models, *TREATMENT effectiveness |
| مصطلحات جغرافية: |
TAIWAN |
| مستخلص: |
Background: The treatment effects on hospitalization for heart failure (hHF) from sodium-glucose cotransporter 2 (SGLT2) inhibitors may vary among type 2 diabetes (T2D) patients depending on whether or not they have established atherosclerotic cardiovascular diseases (ASCVD). We aimed to examine differences in hHF outcomes after dapagliflozin or empagliflozin use between T2D patients with and without a history of established ASCVD. Methods: We conducted a retrospective multi-institutional cohort study in Taiwan. We included T2D patients newly receiving dapagliflozin or empagliflozin during 2016–2019, and followed them up until December 31, 2020. We implemented 1:1 propensity score matching to create homogenous groups for comparisons. We generated Cox proportional hazard models to compare the risk of hHF between dapagliflozin and empagliflozin (reference group). We included interaction terms of SGLT2 inhibitor and ASCVD history in the regression models to examine effect modification by ASCVD. Results: We included a total cohort of 9,586 dapagliflozin new users and 9,586 matched empagliflozin new users. The overall hHF risks were similar for dapagliflozin and empagliflozin (HR: 0.90, 95% CI 0.74–1.09). However, differential hHF risks between dapagliflozin and empagliflozin were observed only in the subgroup without ASCVD (HR: 0.67, 95% CI 0.49–0.90), while not in the subgroup with ASCVD (HR: 1.12, 95% 0.87–1.45), and the p-value for examining interaction was 0.0097. Conclusion: In this study, history of established ASCVD was associated with different hHF risks among SGLT2 inhibitors. For T2D patients without ASCVD, dapagliflozin may offer a more favorable hHF reduction effect, compared to empagliflozin, in clinical practice. Future prospective studies should be conducted to validate our findings. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder